Dear Editor,

The pharmacological chaperone migalastat is indicated for the treatment of Fabry disease in patients with an amenable *GLA* variant. Amenability is determined by an in vitro, good laboratory practice (GLP)-validated assay using HEK293 cells (GLP-HEK assay) performed at a single, highly experienced, GLP-certified laboratory using rigorous standards and extensive analytical validation to limit inter-assay variability \[[@bb0005]\]. The recent report by Oommen et al. entitled "Inter-assay variability influences migalastat amenability assessments among Fabry disease variants" showed \[[@bb0010]\], despite technical differences between a non-GLP-validated assay and the GLP-HEK assay, 53 out of the 59 *GLA* variants tested in the non-GLP assay matched the GLP-HEK amenability classification \[[@bb0005]\]. Considering the non-GLP assay was done without identical procedures and validated quality standards as in the GLP-HEK assay, differences in results are expected. We noted at least two deviations from the GLP-HEK assay that likely account for the discrepancies reported for 6 variants ([Table 1](#t0005){ref-type="table"}). First, the GLP-HEK assay uses qPCR to directly measure the amount of transfected plasmid DNA for transfection efficiency control \[[@bb0005]\]. The method employed by Oommen et al., an indirect measurement of co-transfected, secreted embryonic alkaline phosphatase (SEAP), may be inaccurate because overexpression of mutant α-galactosidase A (α-Gal A) can affect trafficking and secretion of SEAP \[[@bb0010]\]. Second, Oommen et al. used the relative activity (% of wild type) instead of absolute activity (nmol/mg/h) to calculate the fold-increase in α-Gal A activity in response to migalastat, causing values for 4 variants to narrowly miss the amenability criteria ([Table 1](#t0005){ref-type="table"}).Table 1Comparison of discrepant amenability assay results from Benjamin et al. and Oommen et al.Table 1VariantBenjamin et al \[[@bb0005]\] (GLP-HEK) dataOommen et al \[[@bb0010]\] dataBaseline α-Gal Aα-Gal A activity with 10 μM migalastatMann-Whitney U *P* value (one-tail)Absolute increase (% WT)Relative increase (fold)Relative increase by % WT activityAmenable? (Yes/No)Baseline α-Gal Aα-Gal A activity with 10 μM migalastatMann-Whitney U *P* value (one-tail)Absolute increase (% WT)Relative increase (fold)Amenable? (Yes/No)(nmol/mg/h)(% WT)(nmol/mg/h)(% WT)(nmol/mg/h)(% WT)(nmol/mg/h)(% WT)A108T20,76057.129,39180.80.000223.71.421.41Yes14,28773.316,47684.5NA11.21.15NoS126G34,47683.746,491113.90.000130.21.351.36Yes36,722143.743,598170.6NA26.91.19NoD175E15,72644.318,94653.40.02069.11.201.21Yes23,11057.926,93167.4NA9.61.17NoS304 N30,56394.139,629121.80.000127.71.301.29Yes19,48877.822,62290.4NA12.51.16NoD264ABLDBLDBLDBLDNANANANCNo10204.418407.9NA3.51.80YesS276GBLDBLD6942.00.00012.0NCNCNo12523.0876421.0NA18.07.00Yes[^1][^2]

In conclusion, the concern over assay variability seems unfounded, since amenability to migalastat is determined in a single GLP-certified laboratory. We believe physicians can have a high level of confidence in the approved GLP-HEK assay, which identifies *GLA* variants with the potential to respond to migalastat. Of course, individual response will need to be assessed clinically.

[^1]: The amenability criteria for the GLP-HEK assay are ≥1.20-fold over baseline with an absolute increase of ≥3.0% wild-type α-Gal A activity in the presence of 10 μM migalastat.

[^2]: α-Gal A = α-galactosidase A; BLD = below level of detection; GLP-HEK = good laboratory practice-validated HEK293 cell assay; NA = not applicable; NC = not calculated; WT = wild-type.
